Skip to main content
Equibles
PRLD logo

PRLD · Prelude Therapeutics Inc

Track PRLD — free

Use PRLD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PRLD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.77 +0.10 (+2.72%)
Russell 2000 member Rebalance outlook locked
Market Cap
$309.24M
Shares
79.80M
Volume · Oct 5 324.27K Avg daily vol (3M) 472.8K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.67 Open$3.75 Day$3.63–3.82 52W close$1.19–6.63 Avg vol 30d517K Short int3.6M · 4.5% float · 9.0d Short vol68% Last earningsMar 10, 2026 DataSep 2020–Oct 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026
Q3 2025 earnings call transcript
call held Nov 12, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$22.42M
Trailing 12 months
Net income (TTM)
−$60.49M
Trailing 12 months
Revenue growth YoY
+73.4%
Year over year
Operating margin
-300.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-10.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$151.76M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+29.5%
Year over year · more shares
Price change (1Y)
+154.9%
Trailing year
Short interest
4.5%
Latest settlement · 9.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg −26%
below
RSI (14) 30
oversold
MACD trend Negative
52-week position 46%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −30%
trailing
6-month return −16%
trailing
YTD return +27%
this year
Relative strength −28%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+40% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.54% of float · ▲ +0.9% MoM · 9.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
77 holders — near 3-yr high, broad support
Squeeze score 63
elevated · 0–100
Fundamentals
Strong
Revenue growth +73%
Y/Y
EPS growth +23%
Y/Y
Free cash flow $-56.4M
Quant / Vol
risk profile
Very High
Volatility 198%
annualized · 1-yr
Max drawdown −70%
past year
ATR 9.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
−26% Bearish
RSI (14)
30 Neutral
MACD trend
Negative Bearish
52-week position
46% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+40% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.54% of float · ▲ +0.9% MoM · 9.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
77 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $4 · 46% Range high $7
vs 200-day avg -6% vs 50-day avg -26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PRLD
Prelude Therapeutics Inc
this stock
$309.24M +26.6% +73.4% — 4.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
77
% held
62.5%
Net QoQ
+19.1M sh
Top holder
ORBIMED ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
70
View
Short & Settlement
Short Interest Rising
Shares short
3.6M
Days to cover
9.0d
Change
+33.0K sh
View
Short Volume
Short vol %
68%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
114
Value
$523
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
40.1%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$12.1M
Net income (FY)
$-99.5M
EPS diluted
$-1.29
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 10, 2026
This year
17
View
Exempt Offerings
Offering
$50.0M
Filed
Aug 28, 2020
View
Earnings & Events
Webcasts
Last webcast
Sep 16, 2026
View

Performance

5D 20D 120D MTD YTD
PRLD -5.3% -30.1% -16.0% -6.1% +26.6%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -5.1% -29.6% -28.2% -7.1% +13.7%
Key facts CIK 1678660 CUSIP 74065P101 13F (30d) 1 filings 1 filers Visit website Investor relations